45 The Role of the Biliary and Gut Microbiome in the Progression of Cholangiocarcinoma and Primary Sclerosing Cholangitis
Katsuyuki Miyabe(Mayo Clinic in Arizona), Lewis R. Roberts(Mayo Clinic), Andrea A. Gossard(Mayo Clinic), Nicholas Chia(Mayo Clinic), Felicity Enders(Mayo Clinic), Nicha Wongjarupong(Mayo Clinic in Arizona), Mark Topazian(Mayo Clinic), Marina Walther-António(WinnMed), Fatima Hassan(Mayo Clinic in Arizona), Purna Kashyap(Mayo Clinic), Hamdi A. Ali(Mayo Clinic in Arizona), Hawa M. Ali(Mayo Clinic in Arizona), Stephen Johnson(Mayo Clinic), Sravanthi Lavu(Mayo Clinic), Vinay Chandrasekhara(University of Pennsylvania Health System), Jun Chen(University of Pennsylvania), Janet Yao(Mayo Clinic), Sean C. Harrington(Mayo Clinic), Sumera Rizvi(Mayo Clinic in Arizona), Sharad Oli(Mayo Clinic in Arizona), Nasra H. Giama(Mayo Clinic), Gregory J. Gores(Mayo Clinic in Arizona)
Cited by 1
Related Papers
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
|Nature Medicine|2013|4.4k
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k